Literature DB >> 1572772

Local growth and the prognosis of osteosarcoma.

P Wuisman1, W F Enneking, A Roesner.   

Abstract

We have analysed 63 patients who had stage II osteosarcoma of the distal femur (32) or proximal tibia (31) to determine the patterns of disease-free and overall survival in relation to local growth. All had neoadjuvant chemotherapy. The extent of local growth predicts both types of survival in these tumours.

Entities:  

Mesh:

Year:  1992        PMID: 1572772     DOI: 10.1007/bf00182986

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  17 in total

1.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

Authors:  K Winkler; G Beron; G Delling; U Heise; H Kabisch; C Purfürst; J Berger; J Ritter; H Jürgens; V Gerein
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

2.  Clinical prognostic factors in osteosarcoma.

Authors:  R Simon
Journal:  Cancer Treat Rep       Date:  1978-02

3.  Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur.

Authors:  M A Simon; M A Aschliman; N Thomas; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1986-12       Impact factor: 5.284

Review 4.  The therapy of osteogenic sarcoma: current status and thoughts for the future.

Authors:  M A Friedman; S K Carter
Journal:  J Surg Oncol       Date:  1972       Impact factor: 3.454

5.  Tumor infiltration of the bone marrow: comparative study using computed tomography.

Authors:  G Hermann; J S Rose; L Strauss
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

6.  The effect of local extent of the tumor on prognosis in osteosarcoma.

Authors:  S S Spanier; J J Shuster; R A Vander Griend
Journal:  J Bone Joint Surg Am       Date:  1990-06       Impact factor: 5.284

7.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.

Authors:  G Bacci; P Picci; P Ruggieri; M Mercuri; M Avella; R Capanna; A Brach Del Prever; A Mancini; F Gherlinzoni; G Padovani
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

8.  Prognostic factors in osteosarcomas. A regression analysis.

Authors:  S M Bentzen; H S Poulsen; S Kaae; O M Jensen; H Johansen; H T Mouridsen; S Daugaard; C Arnoldi
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

9.  Staging of intraosseous extent of osteosarcoma: correlation of preoperative CT and MR imaging with pathologic macroslides.

Authors:  T Gillespy; M Manfrini; P Ruggieri; S S Spanier; H Pettersson; D S Springfield
Journal:  Radiology       Date:  1988-06       Impact factor: 11.105

10.  Prognostic variables in osteosarcoma: a multi-institutional study.

Authors:  W F Taylor; J C Ivins; K K Unni; J W Beabout; H J Golenzer; L E Black
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506

View more
  2 in total

1.  Development of a Simple Risk Model to Predict Mortality in Patients With Osteosarcoma of the Extremity.

Authors:  Yu Chen; Chao Li; Xin Wang; Zhiyong Liu; Zhigang Ren
Journal:  Front Med (Lausanne)       Date:  2022-05-23

2.  Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.